Topical timolol maleate might adversely affect serum lipoproteins.
Conflicting observations have been reported about the effects of topically administered timolol maleate on serum lipoproteins. We therefore considered this issue in a series of eight glaucoma patients receiving timolol maleate. Cholesterol and triglycerides were measured in plasma and in low-density lipoproteins (LDL), and high-density lipoproteins (HDL), both before and following three months of treatment. Following the treatment, the mean atherogenic index was increased from 2.72 to 3.38 (p = 0.012). This suggests that the atherogenic index should be determined before and during timolol maleate treatment in high-risk cardiovascular patients.
Safran
A B
AB
Department of Ophthalmology, Geneva University Hospital, Switzerland.
Simona
F
F
Sansonetti
A
A
Pometta
D
D
James
R
R
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005901:Glaucoma / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D006951:Hyperlipoproteinemias / Q000139:chemically induced*; D008074:Lipoproteins / Q000097:blood*; D008875:Middle Aged; D009883:Ophthalmic Solutions; D013999:Timolol / Q000008:administration & dosage / Q000009:adverse effects*
D008074:Lipoproteins; D009883:Ophthalmic Solutions; D013999:Timolol